Details

Autor(en) / Beteiligte

• Le Bras, Alicia
• Belkacemi, Yazid
• Bourgier, Celine
• Gabelle-Flandin, Isabelle
• Petit, Adeline
• Guilbert, Philippe
• Geffrelot, Julien
• Racadot, Severine
• Rivin Del Campo, Eleonor
• Hanzen, Chantal
• Charra Brunaud, Claire
• Auzac, Guillaume
• Lacornerie, Thomas
• Lemonnier, Jerome
• Lartigau, Eric
• Durand-Zaleski, Isabelle

Titel

Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial

Ist Teil von

• Radiotherapy and oncology, 2023-10, Vol.187, p.109818-109818, Article 109818

Ort / Verlag

Ireland: Elsevier B.V

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• •The APBI is associated with a lower average cost compared to the WBI.•There is no difference in outcome measured by QALYs at three years.•The APBI is a good option to face an increasing demand for treatments. This economic evaluation reports the incremental cost-utility ratio and national budget impact in France of accelerated partial breast irradiation (APBI) vs standard or hypofractionated whole breast irradiation (WBI) in breast cancer patients at low risk of local recurrence. We compared 490 women randomized to the APBI (ten fractions delivered twice daily over one week) with 488 women in the WBI arm (one fraction per day delivered five days per week over three or six weeks). We took the perspective of the French national health insurance with a three-year time horizon. The outcome was quality-adjusted life years (QALYs). The incremental cost-effectiveness ratio was estimated and uncertainty was explored by probabilistic bootstrapping. Transportation and sick leave costs were added in a sensitivity analysis and a national budget impact analysis based on the incidence of breast cancer estimates in France performed. At three years, the average cost per patient was €2,549 (±1,954) in the APBI arm and €4,468 (±1,586) in the WBI arm (p-value<0.001), radiotherapy was the main driver of the difference between the two arms. No significant difference was found in QALYs. For an average of 60,000 new cases of breast cancer diagnosed annually in France, 28,000 would be eligible for treatment with APBI. A 100% uptake of APBI would result in a yearly30 million€ cost saving. APBI for the treatment of postmenopausal women with early-stage breast cancer is cost saving, with no difference in outcome measured by QALYs.